We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+132.32%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$742M
AUM Growth
+$199M
Cap. Flow
+$27.6M
Cap. Flow %
3.72%
Top 10 Hldgs %
43.53%
Holding
99
New
34
Increased
28
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$33.1M
2
RNAM
Avidity Biosciences
RNAM
+$17.6M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$14.8M
4
GUTS icon
Fractyl Health
GUTS
+$13.5M
5
BIIB icon
Biogen
BIIB
+$10.9M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$39M
2
VRNA
Verona Pharma
VRNA
+$33.9M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.5M
4
ETNB
89bio
ETNB
+$20M
5
SLNO
Soleno Therapeutics
SLNO
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
51
Kiniksa Pharmaceuticals
KNSA
$6.1B
$3.45M 0.47%
88,910
+12,951
+17% +$421K
CNTA
52
DELISTED
Centessa Pharmaceuticals
CNTA
$3.43M 0.46%
141,238
+136,238
+2,725% +$2.42M
EYPT icon
53
EyePoint Inc
EYPT
$1.08B
$3.29M 0.44%
+230,837
New +$2.66M
SION
54
Sionna Therapeutics
SION
$2.11B
$3.2M 0.43%
108,801
-77,214
-42% -$1.68M
ZURA icon
55
Zura Bio
ZURA
$526M
$3.12M 0.42%
+720,452
New +$1.3M
MLYS icon
56
Mineralys Therapeutics
MLYS
$2.31B
$3.03M 0.41%
80,000
-35,282
-31% -$763K
ERAS icon
57
Erasca
ERAS
$6.48B
$2.98M 0.4%
1,368,075
-1,201,516
-47% -$1.91M
PRAX icon
58
Praxis Precision Medicines
PRAX
$8.58B
$2.71M 0.37%
51,210
+41,210
+412% +$2M
ELUT icon
59
Elutia
ELUT
$40M
$2.54M 0.34%
2,850,987
+89,303
+3% +$166K
DCTH icon
60
Delcath Systems
DCTH
$416M
$2.19M 0.29%
203,386
+100,360
+97% +$1.12M
CRNX icon
61
Crinetics Pharmaceuticals
CRNX
$8.85B
$2.08M 0.28%
+50,000
New +$1.6M
CAMP icon
62
CAMP4 Therapeutics
CAMP
$180M
$1.96M 0.26%
+653,594
New +$1.21M
CTNM
63
Contineum Therapeutics
CTNM
$589M
$1.95M 0.26%
+166,161
New +$1.34M
DYN icon
64
Dyne Therapeutics
DYN
$4.8B
$1.26M 0.17%
+100,000
New +$1.14M
LBRX
65
LB Pharmaceuticals
LBRX
$1.17B
$1.11M 0.15%
+70,000
New +$1.11M
CAPR icon
66
PUT
Capricor Therapeutics
CAPR
$243M
$1.04M 0.14%
144,700
– –
MRSN
67
DELISTED
Mersana Therapeutics
MRSN
$1.04M 0.14%
133,636
+8,499
+7% +$63.8K
RADX
68
Radiopharm Theranostics
RADX
$25.2M
$1.03M 0.14%
187,406
– –
ATYR
69
PUT
aTyr Pharma
ATYR
$47.1M
$901K 0.12%
+1,250,000
New +$5.66M
IMVT icon
70
Immunovant
IMVT
$8.11B
$806K 0.11%
+50,000
New +$809K
ARCT icon
71
PUT
Arcturus Therapeutics
ARCT
$168M
$774K 0.1%
+42,000
New +$675K
SNDX icon
72
CALL
Syndax Pharmaceuticals
SNDX
$1.73B
$770K 0.1%
50,000
– –
RARE icon
73
PUT
Ultragenyx Pharmaceutical
RARE
$2.56B
$752K 0.1%
+25,000
New +$750K
MLTX icon
74
CALL
MoonLake Immunotherapeutics
MLTX
$1.62B
$466K 0.06%
+65,000
New +$3.39M
MODD icon
75
Modular Medical
MODD
$11.2M
$448K 0.06%
21,318
-2,361
-10% -$50.8K
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Silverarc Capital Management held 99 positions worth $742M, up 37% from $542M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $27.6M of net new capital in Q3 2025, opening 34 new positions and adding to 28 existing holdings. Its largest new stake was Abivax: 539,704 shares worth $45.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was UroGen Pharma, an estimated $7.99M trimmed.

  • Silverarc Capital Management's largest Q3 2025 buy was Abivax: 539,704 shares worth $45.8M.
  • Silverarc Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $17.6M increase.
  • Silverarc Capital Management's biggest Q3 2025 reduction was UroGen Pharma, cutting an estimated $7.99M.
  • Silverarc Capital Management fully exited Merus in Q3 2025, selling an estimated $39M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $742M portfolio in Q3 2025.
  • Silverarc Capital Management opened 34 new positions and closed 17 in Q3 2025.
  • Silverarc Capital Management's portfolio value rose 37% quarter-over-quarter to $742M.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.